AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 03:42:21 2025-07-16 am EDT			5-day change	1st Jan Change
10,387.00 ^GBX	-1.04%		+0.15%	-0.86%

03:02am	AstraZeneca's Anselamimab Treatment Fails to Reach Primary Goal in Late-Stage Trial	DJ
02:52am	AstraZeneca's amyloidosis treatment fails main goal in late-stage study	RE

AstraZeneca Says Imfinzi Combo Boosts Event-Free Survival in Gastric Cancer Trial

Published on 06/02/2025 at 04:18

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AstraZeneca PLC

AstraZeneca's Anselamimab Treatment Fails to Reach Primary Goal in Late-Stage Trial	03:02am	DJ
AstraZeneca's amyloidosis treatment fails main goal in late-stage study	02:52am	RE
AstraZeneca: mixed phase III trial results for anselamimab	02:50am
AstraZeneca Says Phase 3 Trial for Amyloidosis Medication Fails to Meet Primary Endpoint	02:25am	MT
AstraZeneca drug fails main goal of late-stage amyloidosis study	02:14am	RE
AstraZeneca's Anselamimab in AL amyloidosis did not meet primary endpoint in overall patient population	02:09am	RE
Barclays: AstraZeneca's Q2 Results to Demonstrate 'Resilience' Amid Headwinds	Jul. 15	MT
European Equities Close Mixed in Monday Trading; EU Signals Readiness to Retaliate Against US Tariffs	Jul. 14	MT
UK Shares Start Week in Green on Government Stimuli; AstraZeneca Adds 2%	Jul. 14	MT
ASTRAZENECA : UBS remains its Buy rating	Jul. 14	ZD
FTSE 100 hits fresh record high on rate cut optimism	Jul. 14	RE
FTSE 100 hits fresh record high on rate cut optimism	Jul. 14	RE
European shares end lower as Trump's tariff threats keep markets on edge	Jul. 14	RE
European shares end lower as Trump's tariff threats keep markets on edge	Jul. 14	RE
FTSE 100 thrives but tariff threat hurts Europe	Jul. 14	AN
AstraZeneca plc Announces Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients with Undunded or Treatment Resistant Hypertension	Jul. 14	CI
Astrazeneca's Phase 3 Trial of Baxdrostat in Hypertension Meets Primary, Secondary Endpoints	Jul. 14	MT
AstraZeneca drug lowers high blood pressure in late-stage study; shares rise	Jul. 14	RE
ASTRAZENECA : JP Morgan keeps its Buy rating	Jul. 14	ZD
AstraZeneca: conclusive results against hypertension	Jul. 14
Stockholm Bullets: Lifco Plummets After Missing Expectations	Jul. 14	FW
AstraZeneca drug may lead to lower blood pressure, trial suggests	Jul. 14	AN
FTSE 100 up but tariff woe hits European peers	Jul. 14	AN
AstraZeneca drug meets all goals in high blood pressure study	Jul. 14	RE
AstraZeneca says baxdrostat met primary and secondary endpoints in Phase III trial	Jul. 14	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

Jul. 29 - Q2 2025 Earnings Release

More about the company